The University of Adelaide, School of Animal and Veterinary Sciences, Roseworthy, SA 5371, Australia.
Epilepsy Behav. 2013 Jan;26(1):64-6. doi: 10.1016/j.yebeh.2012.10.032. Epub 2012 Dec 7.
There have been considerable debates about bioequivalence and generic substitution of certain critical care drugs. We aimed to understand patient attitudes and perceptions about generic substitution in the treatment of epilepsy. In this pilot study, a self-administered anonymous survey was completed by 47 patients with epilepsy. The response rate by postal mail was 6.7%. More than 70% of the patients were concerned about the effectiveness of generic antiepileptic drugs, and 68% of the patients were not comfortable receiving generics to treat their epilepsy. About 87% of the patients thought that their antiepileptic drug should only be substituted with a generic with their consent, and 64% of the patients believed that substitution should only take place with the consent of their doctor. Considerable concern exists among patients about generic substitution in the treatment of epilepsy. More data regarding whether generic antiepileptic drugs are bioequivalent in clinical situations would help to address patient concerns.
关于某些重症监护药物的生物等效性和仿制药替代存在大量争论。我们旨在了解患者对癫痫治疗中仿制药替代的态度和看法。在这项初步研究中,47 名癫痫患者完成了一份自行填写的匿名调查问卷。通过邮寄的回复率为 6.7%。超过 70%的患者担心仿制药的疗效,68%的患者在接受治疗癫痫的仿制药时感到不舒服。约 87%的患者认为他们的抗癫痫药物只能在他们同意的情况下用仿制药替代,64%的患者认为只有在医生同意的情况下才能进行替代。患者对癫痫治疗中的仿制药替代存在相当大的担忧。关于在临床情况下仿制药是否具有生物等效性的更多数据将有助于解决患者的担忧。